Zini Chiara, Hipp Elisabeth, Thomas Stephen, Napoli Alessandro, Catalano Carlo, Oto Aytekin
Chiara Zini, Alessandro Napoli, Carlo Catalano, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
World J Radiol. 2012 Jun 28;4(6):247-52. doi: 10.4329/wjr.v4.i6.247.
Prostate cancer (PC) is one of the most frequently diagnosed cancers in men. There are a number of treatment options for PC with a different therapeutic approach between USA and Europe. Radical prostatectomy is one of the most used therapies but focal gland therapy is an emerging approach, especially for localized tumors. In this scenario, high intensity focused ultrasound (HIFU) has been incorporated in certain medical association guidelines. HIFU has been employed for about 10 years especially for localized PC. Results are promising with a 5-year biochemical survival rate ranging from 45% to 84%. Collateral events are rare and HIFU retreatment is not common. Magnetic resonance guided focused ultrasound surgery (MRgFUS) was recently presented as a method for ablation with focused ultrasound under magnetic resonance imaging guidance. It has the advantage of improved targeting and real time temperature monitoring but only a few studies have been conducted with human patients. The aim of this review is to describe the current status of HIFU and MRgFUS in the therapy of PC.
前列腺癌（PC）是男性中最常被诊断出的癌症之一。对于PC有多种治疗选择，美国和欧洲的治疗方法有所不同。根治性前列腺切除术是最常用的疗法之一，但局部腺体治疗是一种新兴方法，尤其是对于局限性肿瘤。在这种情况下，高强度聚焦超声（HIFU）已被纳入某些医学协会指南。HIFU已应用约10年，特别是用于局限性PC。结果很有前景，5年生化生存率在45%至84%之间。附带事件很少见，HIFU再次治疗并不常见。磁共振引导聚焦超声手术（MRgFUS）最近作为一种在磁共振成像引导下用聚焦超声进行消融的方法被提出。它具有改善靶向性和实时温度监测的优点，但仅对少数人类患者进行了研究。本综述的目的是描述HIFU和MRgFUS在PC治疗中的现状。
